{"nctId":"NCT00763867","briefTitle":"Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)","startDateStruct":{"date":"2008-09"},"conditions":["Heart Failure"],"count":216,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Sildenafil","type":"EXPERIMENTAL","interventionNames":["Drug: Sildenafil"]}],"interventions":[{"name":"Placebo","otherNames":["Sugar pill to mimic Sildenafil"]},{"name":"Sildenafil","otherNames":["Active Sildenafil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous clinical diagnosis of heart failure with current New York Heart Association (NYHA) Class II-IV symptoms\n* Has experienced at least one of the following in the 12 months before study entry:\n\n  * Hospitalization for decompensated heart failure\n  * Acute treatment with intravenous loop diuretic or hemofiltration\n  * Mean pulmonary capillary wedge pressure greater than 15 mm Hg or left ventricular end diastolic pressure (LVEDP) greater than 18 mm Hg at catheterization for dyspnea\n  * Long term treatment with a loop diuretic and chronic diastolic dysfunction on echocardiography, as determined by left atrial enlargement\n* Left ventricular ejection fraction greater than or equal to 50%, as determined by a clinical echocardiogram or ventriculogram in the 12 months before study entry\n* Receiving stable medical therapy in the 30 days before study entry, as determined by no addition or removal of angiotensin converting enzyme inhibitor (ACE), angiotensin receptor blocker (ARB), beta-blockers, or calcium channel blockers (CCB) and no change in dosage of ACE, ARBs, beta-blockers, or CCBs of more than 100%\n\nExclusion Criteria:\n\n* Has a neuromuscular, orthopedic, or other non-cardiac condition that prevents individual from exercise testing on a bicycle ergometer or from walking in a hallway\n* Non-cardiac condition that limits life expectancy to less than 1 year at the time of study entry, based on the judgment of the physician\n* Current or anticipated future need for nitrate therapy\n* Valve disease (i.e., greater than mild aortic or mitral stenosis; greater than moderate aortic or mitral regurgitation)\n* Hypertrophic cardiomyopathy\n* Infiltrative or inflammatory myocardial disease (e.g., amyloid, sarcoid)\n* Pericardial disease\n* Primary pulmonary arteriopathy\n* Has experienced a heart attack or unstable angina, or has undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) in the 60 days before study entry, or requires either PTCA or CABG at the time of study entry\n* Other clinically important causes of dyspnea, such as morbid obesity or significant lung disease, as defined by clinical judgment or use of steroids or oxygen for lung disease\n* Systolic blood pressure less than 110 mm Hg or greater than 180 mm Hg\n* Diastolic blood pressure less than 40 mm Hg or greater than 100 mm Hg\n* Resting heart rate (HR) greater than 100 bpm\n* History of reduced ejection fraction (less than 50%)\n* Implanted metallic device that will interfere with MRI examination (in people without atrial fibrillation)\n* Severe kidney dysfunction (estimated glomerular filtration rate \\[GFR\\] less than 20 ml/min/1.73m2 by modified modification of diet in renal disease \\[MDRD\\] equation)\n* Pregnant or not using an effective form of contraception\n* Hemoglobin level of less than 10 g/dL\n* Taking alpha antagonists or cytochrome P450 3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine, or serum protease inhibitors for HIV)\n* Retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy, or unexplained visual disturbance\n* Sickle cell anemia, multiple myeloma, leukemia, or penile deformities that increase the risk for priapism (e.g., angulation, cavernosal fibrosis, Peyronie's disease)\n* Severe liver disease (aspartate aminotransferase \\[AST\\] level greater than three times the normal limit, alkaline phosphatase or bilirubin greater than two times the normal limit)\n* In being consistent with American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, people with dyspnea and risk factors for coronary artery disease should have had a stress test and those people with a clinically indicated stress test demonstrating significant ischemia in the 1 year before study entry will be excluded.\n* Listed for heart transplantation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Exercise Capacity, as Determined by Peak Oxygen Uptake","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"2.00"},{"groupId":"OG001","value":"-0.12","spread":"2.29"}]}]}]},{"type":"SECONDARY","title":"Exercise Capacity, as Determined by Peak Oxygen Uptake","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"1.70"},{"groupId":"OG001","value":"0.03","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"Exercise Capacity as Determined by Walk Distance","description":"6 Minute Walk Distance","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"83.7"},{"groupId":"OG001","value":"5.2","spread":"69.1"}]}]}]},{"type":"SECONDARY","title":"Composite Score Reflective of Clinical Status","description":"Participants ranked sequentially with ranking stratified in one of three tiers based on:\n\n1. Death (lowest tier) The person with the shortest time from randomization to death is given the lowest rank within the tier.\n2. Hospitalizations due to cardiovascular or renal causes (middle tier) For patients alive, the ranking within this tier is based on time to hospitalization from randomization date. The person with the first cardiovascular or renal cause hospitalization will be given the lowest rank within the tier.\n3. Change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) from baseline (highest tier)\n\nThe use of three tiers within the ranking reflects the greater adverse impact of death or cardiovascular hospitalization on clinical status without an arbitrary assignment as to the relative value of these events in relation to changes in quality of life. Rank order: 1-189 (higher values are better)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":"55.0"},{"groupId":"OG001","value":"94.2","spread":"54.6"}]}]}]},{"type":"SECONDARY","title":"Exercise Capacity as Determined by Walk Distance","description":"6 minute walk distance","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"88.6"},{"groupId":"OG001","value":"12.0","spread":"94.2"}]}]}]},{"type":"SECONDARY","title":"Cardiopulmonary Exercise Test (CPET) Duration","description":"To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.61"},{"groupId":"OG001","value":"-0.15","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Cardiopulmonary Exercise Test (CPET) Duration","description":"To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.82","spread":"2.63"},{"groupId":"OG001","value":"9.77","spread":"3.21"}]}]}]},{"type":"SECONDARY","title":"Ventilatory Anaerobic Threshold","description":"To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"1.14"},{"groupId":"OG001","value":"0.06","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"Ventilatory Anaerobic Threshold","description":"To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"1.26"},{"groupId":"OG001","value":"0.17","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Minnesota Living With Heart Failure Questionnaire (MLWHFQ)","description":"The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment.\n\nTotal score: 0 - 105 Physical subscore: 0 - 40 Emotional subscore: 0 - 25","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"22.0"},{"groupId":"OG001","value":"-6.2","spread":"20.8"}]}]}]},{"type":"SECONDARY","title":"Minnesota Living With Heart Failure Questionnaire","description":"The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"24.2"},{"groupId":"OG001","value":"-8.3","spread":"19.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular Mass","description":"A decrease in LV Mass is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"14.43"},{"groupId":"OG001","value":"-0.07","spread":"14.93"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular Mass Index","description":"A decrease in Left Ventricular Mass Index is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"6.54"},{"groupId":"OG001","value":"0.61","spread":"6.96"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular End Diastolic Volume","description":"An increase in Left Ventricular End Diastolic Volume is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.70","spread":"21.03"},{"groupId":"OG001","value":"3.61","spread":"25.02"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular End Diastolic Volume Index","description":"An increase in Left Ventricular End Diastolic Volume Index is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"9.45"},{"groupId":"OG001","value":"2.11","spread":"11.21"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular End Systolic Volume Index","description":"An increase in Left Ventricular End Systolic Volume Index is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"4.09"},{"groupId":"OG001","value":"0.25","spread":"6.12"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Left Ventricular Ejection Fraction (LVEF)","description":"An increase in LVEF is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"4.28"},{"groupId":"OG001","value":"0.62","spread":"4.88"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Echocardiogram Left Ventricular Mass","description":"A decrease in Left Ventricular Mass is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"47.36"},{"groupId":"OG001","value":"-8.79","spread":"35.60"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Medial Diastolic Elastance","description":"A decrease in Medial Diastolic Elastance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.11"},{"groupId":"OG001","value":"-0.01","spread":"0.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lateral Diastolic Elastance","description":"A decrease in Lateral Diastolic Elastance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.09"},{"groupId":"OG001","value":"-0.01","spread":"0.08"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Medial Left Ventricular Relaxation","description":"An increase in Left Ventricular relaxation is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.02"},{"groupId":"OG001","value":"-0.00","spread":"0.02"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lateral Left Ventricular Relaxation","description":"An increase in Left Ventricular relaxation is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.02"},{"groupId":"OG001","value":"-0.00","spread":"0.02"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Medial Filling Pressure","description":"A decrease in medial filling pressure is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.64","spread":"6.83"},{"groupId":"OG001","value":"0.33","spread":"6.04"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lateral Filling Pressure","description":"A decrease in lateral filling pressure is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"5.17"},{"groupId":"OG001","value":"-0.04","spread":"5.68"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"ECHO Effective Arterial Elastance","description":"A decrease in Effective Arterial Elastance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.46"},{"groupId":"OG001","value":"-0.07","spread":"0.36"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"ECHO Systemic Vascular Resistance","description":"A decrease in Systemic Vascular Resistance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.46"},{"groupId":"OG001","value":"-0.01","spread":"0.35"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Effective Arterial Elastance","description":"A decrease in Effective Arterial Elastance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.44"},{"groupId":"OG001","value":"-0.15","spread":"0.38"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Systemic Vascular Resistance","description":"A decrease in Systemic Vascular Resistance is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.57"},{"groupId":"OG001","value":"-0.10","spread":"0.39"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Aortic Thickness","description":"A decrease in Aortic Thickness is considered an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.17"},{"groupId":"OG001","value":"-0.03","spread":"0.18"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MRI Aortic Distensibility","description":"An increase in Aortic Distensibility is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.66"},{"groupId":"OG001","value":"0.29","spread":"1.13"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"ECHO Pulmonary Artery Systolic Pressure","description":"A decrease in Pulmonary Artery Systolic Pressure is considered to be an improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"12.43"},{"groupId":"OG001","value":"0.32","spread":"10.09"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Best Available Creatinine","description":"Best available=local lab results only when core lab results not available","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.23"},{"groupId":"OG001","value":"0.09","spread":"0.29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Best Available Glomerular Filtration Rate (GFR)","description":"Best available=local lab results when core lab results not available","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"15.02"},{"groupId":"OG001","value":"-3.27","spread":"12.16"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cystatin C","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.27"},{"groupId":"OG001","value":"0.10","spread":"0.29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Uric Acid","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"1.79"},{"groupId":"OG001","value":"0.51","spread":"1.80"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.52","spread":"799.87"},{"groupId":"OG001","value":"158.25","spread":"538.85"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Aldosterone","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.04","spread":"220.06"},{"groupId":"OG001","value":"1.22","spread":"213.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"High Sensitivity Troponin I","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":"29.71"},{"groupId":"OG001","value":"11.11","spread":"62.49"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Procollagen III N-terminal Peptide","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"5.22"},{"groupId":"OG001","value":"0.41","spread":"3.90"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Endothelin-1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.51"},{"groupId":"OG001","value":"0.49","spread":"1.29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"High Sensitivity C-Reactive Protein","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"7.20"},{"groupId":"OG001","value":"0.32","spread":"5.49"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Collagen Type I (CITP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"4.03"},{"groupId":"OG001","value":"5.61","spread":"48.96"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cyclic Guanosine Monophosphate (cGMP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"37.05"},{"groupId":"OG001","value":"8.72","spread":"30.22"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Galectin 3","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"9.63"},{"groupId":"OG001","value":"1.26","spread":"7.71"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Furosemide-Equivalent Dose","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"35.44"},{"groupId":"OG001","value":"7.27","spread":"59.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":103},"commonTop":["Headache","Diarhea","Dizziness","Flushing","Visual Impairment"]}}}